MarginProbe System May Reduce Need for Repeat Surgery After Initial Lumpectomy
(GOODYEAR, Ariz.) – June 15, 2014 – Cancer Treatment Centers of America® (CTCA) at Western Regional Medical Center (Western) has become the first hospital in Arizona to deploy the MarginProbe® System, a new FDA-approved intraoperative tissue-assessment tool for breast-cancer surgery. The MarginProbe assess the electromagnetic properties of cells along the edges of breast tissue removed from patients with breast cancer during lumpectomy surgery, while a patient is still in the operating room, potentially reducing the need for a repeat surgical procedure later.
“We are proud to be the first hospital in Arizona to utilize this cutting-edge technology,” said Matt McGuire, President and CEO, CTCA® at Western. “The MarginProbe gives our patients greater peace of mind, knowing that we are utilizing every available resource to potentially prevent a repeat surgery.”
During a lumpectomy, the cancerous breast tumor and a small amount of tissue surrounding the tumor are removed. The purpose of removing normal tissue surrounding the tumor is to ensure “clear margins” – no tumor cells on the surface of the breast tissue removed. Research has shown that cancer cells have a distinctive electromagnetic signature, which is different from that of healthy cells. The MarginProbe gathers this electromagnetic signature and significantly improves surgeons’ ability to identify “cancer on the margins” at the time of breast cancer surgery.
“This innovative new technology, which is currently available at only 14 centers in the United States, revolutionizes the treatment that we provide our breast cancer patients who are undergoing breast-conserving surgery,” said Dr. Robert Wascher, Surgical Oncologist and Chief of Surgery, CTCA Western, and Clinical Professor of Surgery at the University of Arizona College of Medicine (Phoenix). “Previously, the only option available for accurately testing the margins of breast tissue removed by lumpectomy was to send that tissue to a lab, which requires several days before the final results become available. Now, however, the MarginProbe® offers surgeons and their patients a real-time solution for assessing the margin status of lumpectomy specimens within the operating room, potentially eliminating the need for additional surgery for many patients.”
With MarginProbe, a surgeon is able to scan for cancer on the margins in a matter of minutes while the patient is still under sedation in the operating room. If cancer is found, additional tissue can be removed immediately.
About Cancer Treatment Centers of America®
Cancer Treatment Centers of America Global, Inc. (CTCA), headquartered in Boca Raton, Fla., is a national network of five hospitals that serves adult patients who are fighting cancer. CTCA® offers an integrative approach to care that combines advancements in genomic testing and precision cancer treatment, surgery, radiation, immunotherapy and chemotherapy, with evidence-based supportive therapies designed to help patients physically and emotionally by enhancing their quality of life while managing side effects both during and after treatment. CTCA serves patients from around the world at its hospitals in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa. Consistently rated among U.S. hospitals that deliver the highest quality of care and patient experience, CTCA provides patients and their families with comprehensive information about their treatment options and encourages their active participation in treatment decisions. For more information, visit cancercenter.com, Facebook.com/cancercenter and Twitter.com/cancercenter.